05.20.22 -- Enhancing The Patient Experience During Subcutaneous Biologic Delivery

Drug manufacturers have historically faced constraints upon formulations due to device limitations, such as needle length, causing them to work within a narrow design space that has limited drug concentration, patient ease, and usability, impacting dosing regimens and adherence.

Great progress and efforts have been made in offering drug delivery systems for chronic diseases over the past decades. Needle innovations can enable the delivery of larger, more viscous drugs, without compromising end-user experience.

This series of frequently asked questions covers the research and design mindset applied to the development of the BD Neopak™ XtraFlow™ solution and how the anticipated clinical benefits of 8 mm needles will support their broad adoption over time for subcutaneous drug delivery, particularly for use in chronic care settings.

High-volume parenteral delivery systems require consideration of both functional design and human factors to enable successful and consistent, reliable delivery to the target tissue. Examine the influence of needle inner diameter and length on delivery time across a range of fluid viscosities using a prototype auto-injector device.